| Oncology | |||
| NO. | Product Name | Specification | Approved |
| 1 | Anastrozole | USP | DMF |
| 2 | Bicalutamide | USP | FDA approved |
| 3 | Bleomycin sulphate | USP | FDA/COS approved |
| 4 | Capecitabine | Enterprise standard | GMP/EDMF |
| 5 | Carboplatin | USP/EP | GMP/EDMF |
| 6 | Cisplatin | USP/EP | GMP/EDMF |
| 7 | Cladribine | USP | FDA approved |
| 8 | Cyclophosphamide | USP/EP | FDA/COS approved |
| 9 | Cytarabine | USP/EP | FDA/COS approved |
| 10 | Dacarbazine | USP | GMP/EDMF |
| 11 | Dactinomycin | USP | FDA approved |
| 12 | Daunorubicin hcl | USP/EP | FDA approved |
| 13 | Docetaxel | Enterprise standard | GMP/EDMF |
| 14 | Doxorubicin hcl | USP/EP | DMF/COS approved |
| 15 | Epirubicin hcl | EP | DMF/COS approved |
| 16 | Floxuridine | USP | FDA approved |
| 17 | Etoposide | USP | FDA approved |
| 18 | Fluorouracil | USP | GMP/DMF |
| 19 | Fludarabine phosphate | USP,EP | FDA/COS approved |
| 20 | Fulvestrant | Enterprise standard | GMP/EDMF |
| 21 | Gemcitabine hcl | EP | FDA approved |
| 22 | Glufosfamide | Enterprise standard | GMP |
| 23 | Granisetron hcl | USP, EP | FDA/COS approved |
| 24 | Idarubicin hcl | USP | FDA approved |
| 25 | Ifosfamide | USP | FDA approved |
| 26 | Irinotecan hcl | USP | GMP+EDMF |
| 27 | Letrozole | USP/ EP | GMP+EDMF |
| 28 | Leucovorin calcium | USP/EP | FDA approved |
| 29 | Leuprolide acetate | EP | EDMF |
| 30 | Mesna | EP | GMP/FDA/EDMF approved |
| 31 | Methotrexate | USP/EP | COA approved |
| 32 | Mitomycin | USP/EP | FDA/COS approved |
| 33 | Octreotide acetate | EP | EDMF |
| 34 | Oxaliplatin | EP | COS approved |
| 35 | Paclitaxel | USP | EDMF |
| 36 | Pfirarubicin | Enterprise standard | TDP |
| 37 | Pemetrexed disodium | Enterprise standard | GMP/EDMF |
| 38 | Tamoxifen citrate | USP,EP | EDMF |
| 39 | Valrubicin | Enterprise standard | TDP |
| 40 | Vinblastine sulphate | USP | GMP+DMF |
| 41 | Vincristine sulphate | USP,EP | GMP+DMF |
| 42 | Vinorelbine tartrate | USP,EP | FDA/COS approved |
| Note: Products covered by patent in the country of destination will not be supplied to this country. However the final responsibility and risk lies with the buyer. |



